Regeneron's pledge to provide the gene therapy Otarmeni — lunsotogene parveccwha — free in the United States to eligible patients has turned the Commissioner's National Priority Voucher pilot into the case study its critics needed. The FDA approved the therapy on April 24 in a tie for the fastest BLA in modern agency history; the Federal Register's April 23 amendment rescheduled the CNPV public hearing to June 4. [1][2]

The paper tracked this approval at Day Two as an agency-history fact. Sunday converts it into an economics test. Free in the US sounds like access; outside the US it is a paid product. The pilot's question — whether voucher acceleration produces durable access — now has a single product running both halves of the experiment in real time. [3]

The June 4 hearing matters because the comment window has closed. The agency has invited public commentary on the pilot's structure and durability questions, including off-label durability, registries, and post-market access. A 61-day approval with a six-week public hearing is not a long evidentiary cycle; it is a calendar that asks whether the voucher mechanism can hold a public-policy fight at the speed it set for itself. [2]

The next datapoint is the hearing record. Whether the public testimony names price, access, or durability as the pilot's first real test will tell the FDA which question it is being asked to answer.

-- NORA WHITFIELD, Chicago